

Amendments to the Claims

Claims 1-23 (canceled)

24. (new) A hydrochloride salt of *N*-{2-[4-(3-phenyl-4-methoxyphenyl)aminophenyl]ethyl}-(*R*)-2-hydroxy-2-(8-hydroxy-2(1*H*)-quinolinon-5-yl)ethylamine.

25. (new) A pharmaceutical composition comprising a therapeutically effective amount of the compound of Claim 1 and a pharmaceutically-acceptable carrier.

26. (new) The pharmaceutical composition of Claim 25, wherein the composition is formulated for administration by inhalation.

27. (new) The pharmaceutical composition of Claim 25 wherein the composition further comprises a therapeutically effective amount of a steroidal anti-inflammatory agent.

28. (new) The pharmaceutical composition of Claim 25, wherein the composition further comprises a therapeutically effective amount of one or more therapeutic agents selected from the group consisting of a steroidal anti-inflammatory agent, a muscarinic receptor antagonist agent, a phosphodiesterase inhibitor agent, an immunoglobulin antibody, a leukotriene antagonist agent, a cytokine antagonist agent, a protease inhibitor, cromolyn sodium, nedocromil sodium, and sodium cromoglycate.

29. (new) A method of treating a disease or condition in a mammal associated with β_2 adrenergic receptor activity, the method comprising administering to the mammal, a therapeutically effective amount of a pharmaceutical composition of Claim 25.

30. (new) The method of Claim 29 wherein the disease or condition is a pulmonary disease.

31. (new) The method of Claim 30 wherein the pulmonary disease is asthma or chronic obstructive pulmonary disease.

32. (new) The method of Claim 29 wherein the disease or condition is selected from the group consisting of pre-term labor, neurological disorders, cardiac disorders, and inflammation.

33. (new) The method of Claim 29 further comprising administering a therapeutically effective amount of a steroidal anti-inflammatory agent.

34. (new) The method of Claim 29 further comprising administering a therapeutically effective amount of one or more therapeutic agents selected from the group consisting of a steroidal anti-inflammatory agent, a muscarinic receptor antagonist agent, a phosphodiesterase inhibitor agent, an immunoglobulin antibody, a leukotriene antagonist agent, a cytokine antagonist agent, a protease inhibitor, cromolyn sodium, nedocromil sodium, and sodium cromoglycate.